UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of May 2022

Commission File Number: 001-37993

 

 

OBSEVA SA

(Translation of registrant’s name into English)

 

 

Chemin des Aulx, 12

1228 Plan-les-Ouates

Geneva, Switzerland

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:    ☒  Form 20-F    ☐  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

INCORPORATION BY REFERENCE

This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3, as amended (No. 333-221462, 333-233069, 333-260974 and 333-262820) of ObsEva SA (including any prospectuses forming a part of such registration statements) and the registration statements on Form S-8 (Registration No. 333-216170, 333-231629, 333-249457 and 333-263234) of ObsEva SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

 

Exhibit
No.

   

Description

99.1    Press Release dated May 19, 2022.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    ObsEva SA
Date: May 19, 2022     By:  

/s/ Brian O’Callaghan

      Name Brian O’Callaghan
      Title:  Chief Executive Officer

Exhibit 99.1

 

LOGO

ObsEva SA Announces that Shareholders Approved all Board Proposals at its

2022 Annual General Meeting held on May 18, 2022

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

Geneva, Switzerland – May 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that shareholders approved all Board proposals at its 2022 Annual General Meeting held on May 18, 2022.

The approved items are as follows:

 

  1.

Shareholders approved the Annual Report, the Statutory Financial Statements and the Consolidated Financial Statements for Fiscal Year 2021

 

  2.

Shareholders granted discharge to the Members of the Board of Directors and to the Executive Committee for year 2021

 

  3.

Shareholders approved the proposed appropriation of the Financial Results for year 2021

 

  4.

Shareholders approved the proposed elections to the Board of Directors and election of the Chairperson of the Board of Directors

 

  5.

Shareholders approved the proposed elections to the Compensation Committee

 

  6.

Shareholders approved the re-election of PricewaterhouseCoopers SA as ObsEva SA’s Auditors and Independent Registered Public Accounting Firm

 

  7.

Shareholders approved the re-election of Perréard de Boccard SA as Independent Representative

 

  8.

Shareholders approved the proposed compensation of the Board of Directors and the Executive Committee

 

  9.

Shareholders approved the proposed increase of ObsEva SA’s Authorized Share Capital

 

  10.

Shareholders approved the proposed increase of ObsEva SA’s Conditional Share Capital for Financing Purposes

 

  11.

Shareholders approved the proposed increase of ObsEva SA’s Conditional Share Capital for Equity Plans

 

  12.

Shareholders approved the proposed change to ObsEva SA’s Equity Incentive Plan

 

  13.

Shareholders approved the Issuance of Conversion Shares and Warrant Shares under Securities Purchase Agreement

For a detailed agenda, including items submitted to shareholders’ vote and related proposals of the Board of Directors, please refer to the full invitation, which may be found in the Investors / General Meetings section of the company’s website www.ObsEva.com.

 

LOGO

 

To access the general meetings section of the Company’s website, please click here.

To access the AGM 2022 section of the general meetings section directly, please click here.

To access the full invitation to the AGM 2022 directly, please click here.

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s health. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

For further information, please contact:

CEO Office Contact:

Shauna Dillon

Shauna.dillon@obseva.ch

+41 22 552 1550

Investor Contact:

Katja Bührer

Katja.buhrer@obseva.com

+1 (917) 969-3438